China Isotope & Radiation Corporation (HKG:1763)

Market Cap	6.54B +80.6%
Revenue (ttm)	8.35B +13.7%
Net Income	464.77M +6.0%
EPS	1.45 +6.0%
Shares Out	319.87M
PE Ratio	14.07
Forward PE	n/a
Dividend	0.43 (2.04%)
Ex-Dividend Date	Oct 21, 2025

Volume	447,000
Average Volume	189,449
Open	20.30
Previous Close	20.90
Day's Range	20.26 - 21.16
52-Week Range	10.38 - 25.00
Beta	0.59
RSI	46.14
Earnings Date	Mar 27, 2026

About China Isotope & Radiation

China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of nuclides, diagnostic, and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Other Businesses. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmace...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1983
• Employees: 3,361
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1763

Financial Performance

In 2024, China Isotope & Radiation's revenue was 7.57 billion, an increase of 14.16% compared to the previous year's 6.63 billion. Earnings were 406.65 million, an increase of 9.62%.

Financial numbers in CNY